Anil Shanker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/656595/publications.pdf

Version: 2024-02-01

83 papers	1,782 citations	257450 24 h-index	289244 40 g-index
84 all docs	84 docs citations	84 times ranked	2694 citing authors

#	Article	IF	Citations
1	Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition. Journal of Immunology, 2008, 180, 163-170.	0.8	138
2	CD8 T Cell Help for Innate Antitumor Immunity. Journal of Immunology, 2007, 179, 6651-6662.	0.8	94
3	NK cells: immune cross-talk and therapeutic implications. Immunotherapy, 2011, 3, 1143-1166.	2.0	88
4	Critical Neurotransmitters in the Neuroimmune Network. Frontiers in Immunology, 2020, 11, 1869.	4.8	86
5	CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Frontiers in Immunology, 2019, 10, 1906.	4.8	84
6	TNFâ€related apoptosisâ€inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunology and Cell Biology, 2006, 84, 87-98.	2.3	83
7	Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody. Journal of the National Cancer Institute, 2008, 100, 649-662.	6.3	83
8	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine, 2013, 11, 145.	4.4	82
9	Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth. Cancer Research, 2011, 71, 6122-6131.	0.9	64
10	Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex. Molecular Cancer Research, 2010, 8, 729-738.	3.4	63
11	Modulatory effects of bortezomib on host immune cell functions. Immunotherapy, 2015, 7, 1011-1022.	2.0	52
12	Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Research, 2015, 75, 4728-4741.	0.9	49
13	Is thymus redundant after adulthood?. Immunology Letters, 2004, 91, 79-86.	2.5	46
14	Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunology, Immunotherapy, 2011, 60, 1061-1074.	4.2	45
15	Ascitic Growth of a Spontaneous Transplantable T Cell Lymphoma Induces Thymic Involution. Tumor Biology, 2000, 21, 288-298.	1.8	42
16	Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunology Letters, 2016, 169, 61-72.	2.5	42
17	Challenges and future perspectives of T cell immunotherapy in cancer. Immunology Letters, 2015, 166, 117-133.	2.5	41
18	Ascitic Growth of a Spontaneous Transplantable T Cell Lymphoma Induces Thymic Involution. Tumor Biology, 2000, 21, 315-327.	1.8	40

#	Article	IF	Citations
19	Antigen Presented by TumorsIn vivoDetermines the Nature of CD8+ T-Cell Cytotoxicity. Cancer Research, 2009, 69, 6615-6623.	0.9	38
20	Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted Tâ€cell receptor diversity. Immunology, 2010, 129, 41-54.	4.4	36
21	Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget, 2015, 6, 20754-20772.	1.8	34
22	Fus1/Tusc2 Is a Novel Regulator of Mitochondrial Calcium Handling, Ca²⁺-Coupled Mitochondrial Processes, and Ca²⁺-Dependent NFAT and NF-ÎºB Pathways in CD4⁺T Cells. Antioxidants and Redox Signaling, 2014, 20, 1533-1547.	5.4	33
23	Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor TÂcell immunity. , 2019, 7, 95.		31
24	Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-ÎºB crosstalk. Oncotarget, 2015, 6, 32439-32455.	1.8	28
25	Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Research, 2015, 75, 5260-5272.	0.9	26
26	Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin Î±-1. International Journal of Immunopharmacology, 2000, 22, 309-321.	1.1	24
27	Adaptive control of innate immunity. Immunology Letters, 2010, 131, 107-112.	2.5	23
28	Development of Proteasome Inhibitors as Therapeutic Drugs. Journal of Clinical & Cellular Immunology, 2012, 01, 5.	1.5	23
29	Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. FEMS Immunology and Medical Microbiology, 2000, 27, 247-255.	2.7	22
30	Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine, 2016, 84, 74-87.	3.2	22
31	Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging, 2017, 9, 627-649.	3.1	20
32	Thymocyte-Intrinsic Genetic Factors Influence CD8 T Cell Lineage Commitment and Affect Selection of a Tumor-Reactive TCR. Journal of Immunology, 2004, 172, 5069-5077.	0.8	19
33	NK Cells Use NKG2D to Recognize a Mouse Renal Cancer (Renca), yet Require Intercellular Adhesion Molecule-1 Expression on the Tumor Cells for Optimal Perforin-Dependent Effector Function. Journal of Immunology, 2006, 177, 2575-2583.	0.8	19
34	Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget, 2017, 8, 8604-8621.	1.8	16
35	Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1. Frontiers in Immunology, 2021, 12, 607044.	4.8	16
36	Validation of research trajectory 1 of an Exposome framework: Exposure to benzo(a)pyrene confers enhanced susceptibility to bacterial infection. Environmental Research, 2016, 146, 173-184.	7.5	15

#	Article	IF	Citations
37	Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings. Frontiers in Immunology, 2020, 11, 1958.	4.8	15
38	UpdateÂon the current revolution in cancer immunotherapy. Immunotherapy, 2019, 11, 15-20.	2.0	12
39	Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Research, 2021, 81, 3374-3386.	0.9	11
40	Sensitizing Tumor Cells to Immune-Mediated Cytotoxicity. Advances in Experimental Medicine and Biology, 2007, 601, 163-171.	1.6	10
41	Innate-Adaptive Immune Crosstalk 2016. Journal of Immunology Research, 2017, 2017, 1-2.	2.2	8
42	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Nonâ€“Small-Cell LungÂCancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical Lung Cancer, 2020, 21, 520-526.	2.6	8
43	Editorial: Lymphocyte Functional Crosstalk and Regulation. Frontiers in Immunology, 2019, 10, 2916.	4.8	6
44	Antitumor Effect of Some 3d-Metal Complexes of N-Isonicotinoyl-N'-o-Hydroxythiobenzhydrazide. Bioinorganic Chemistry and Applications, 2003, 1, 255-270.	4.1	5
45	Computational properties of mitochondria in T cell activation and fate. Open Biology, 2016, 6, 160192.	3.6	5
46	Tributyltin exposure alters cytokine levels in mouse serum. Journal of Immunotoxicology, 2016, 13, 870-878.	1.7	5
47	Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity. OncoImmunology, 2016, 5, e1122864.	4.6	5
48	Innate-Adaptive Immune Crosstalk. Journal of Immunology Research, 2015, 2015, 1-2.	2.2	4
49	Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications. Cancer Gene Therapy, 2022, 29, 1307-1320.	4.6	4
50	Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy, 2017, 9, 305-308.	2.0	3
51	Promise of Immunotherapy in Lung Cancer. Progress in Tumor Research, 2015, 42, 95-109.	0.1	2
52	Neuroendocrine Crosstalk of Immunity. Journal of Blood & Lymph, 2011, 01, .	0.0	2
53	Cancer therapy by resuscitating Notch immune surveillance. , 2014, 2, .		1
54	The rapid endocytic uptake of fetuinâ€A by adherent tumor cells is mediated by Tollâ€like receptor 4 (TLR4). FEBS Open Bio, 2020, 10, 2722-2732.	2.3	1

#	Article	IF	Citations
55	Abstract 1177: Pharmacological stimulation of DLL1-Notch signaling as an effective cancer immunotherapy. , 2014, , .		1
56	Abstract 4161: Bortezomib enhances expression of effector molecules in antitumor CD8+ T lymphocytes by modulating Notch-NF-kB-miR-155 crosstalk. , 2016, , .		1
57	Corrigendum to â€œImpairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous originâ€•[FEMS Immunol. Med. Microbiol. 27 (2000) 247â€“255]. FEMS Immunology and Medical Microbiology, 2001, 31, 235.	2.7	0
58	Tumor Therapy With Proteasome Inhibitor Bortezomib (Velcade, PS-341) Plus Death Receptor (DR5) Agonist Antibody MD5.1. Journal of Immunotherapy, 2005, 28, 641.	2.4	0
59	Cancer therapy by restoration of immune Notch. , 2013, 1, .		0
60	Bortezomib enhances anti-tumor T cell immunity by remodeling Notch system. , 2014, 2, .		0
61	Cross-talk between CD8+ T cells and natural killers: the role of mitochondrial Aa2+ transport. , 2014, 2, .		0
62	Modulation of anti-tumor lymphocyte function by neurotransmitter glutamate. , 2014, 2, P38.		0
63	From immunogenetic polymorphism to functional antitumor lymphocyte mitochondrial dynamics. , 2015, 3, O13.		0
64	Upregulation of neuroreceptors on CD4+ and CD8+ T cells promotes their anti-tumor function. , 2015, 3, P322.		0
65	Abstract 4251: Murine hepatocellular carcinoma stem cells express pluri-potency-associated transcription factors and are sensitive to immune-mediated apoptosis. , 2010, , .		0
66	Abstract 1931: Impact of bortezomib-induced proteasome inhibitionin vivoon antitumor T cell responses. , 2010, , .		0
67	The Immune Rejection: Lessons from Experimental Models. , 2011, , 17-25.		0
68	Abstract B107: Combination therapy of kidney cancer using bortezomib and natural killer (NK) cell transfer. , 2011, , .		0
69	Abstract B108: Combining Notch immunostimulation and bortezomib with adoptive immunotherapy in breast cancer. , 2011, , .		0
70	Lymphocyte Teamwork in Tumor Rejection. , 2012, , 411-413.		0
71	Abstract A9: Pharmacological stimulation of DLL1-Notch signaling as an antitumor immunotherapy. Clinical Cancer Research, 2012, 18, A9-A9.	7.0	0
72	Abstract B93: Resuscitating cancer immunosurveillance by combining Notch 1 and death receptor-activating therapy.. , 2012, , .		0

#	Article	IF	Citations
73	Abstract 3983: Resuscitating immune surveillance in cancer.. , 2013, , .		0
74	Abstract 3642: Cancer therapy by resuscitating Notch immune surveillance. , 2014, , .		0
75	Abstract 3191: Elevation of tumor-promoting cytokines in mice exposed to the environmental contaminant tributyltin. , 2014, , .		0
76	Abstract 2735: Tributyltin alters the production and secretion of inflammatory cytokines from human and mouse immune cells. , 2015, , .		0
77	Abstract 4059: Crosstalk between CD8+ T and NK cells: fine-tuning of antitumor immune response. , 2015, , .		0
78	Abstract B45: Mitochondrial Ca2+ transport fine-tunes functional cross-talk between antitumor CD8+T lymphocytes and natural killer cells. , 2015, , .		0
79	Abstract 934: Tributyltin-induced dysregulation of inflammatory cytokine levels in human and mouse immune cells. , 2016, , .		0
80	Abstract 5665: Physical crosstalk between CD8+T and natural killer cells elicits antitumor effector response. , 2017, , .		0
81	Abstract 647: Bortezomib enhances CD8+T Lymphocyte antitumor effector function: Potential mechanism(s) via notch regulation. , 2017, , .		0
82	Abstract C135: Notch as an immunologic basis of cancer disparity. , 2020, , .		0
83	Notch as an Immunologic Basis of Cancer Disparities. Cancer Health Disparities, 2019, 3, e1-e10.	0.5	0